Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2016 06:30 ET | Source: Dynavax Technologies

Dynavax Receives Complete Response Letter from U.S. Food and Drug Administration for Biologics License Application for HEPLISAV-B

BERKELEY, CA--(Marketwired - November 14, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...
November 09, 2016 11:00 ET | Source: Dynavax Technologies

Dynavax Presents Early Clinical Data from Lead Cancer Immunotherapy Candidate, SD-101, at Society for Melanoma Research

BERKELEY, CA--(Marketwired - November 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings from an ongoing Phase 1b/2 study investigating SD-101,...
November 07, 2016 06:00 ET | Source: Dynavax Technologies

Dynavax Reports Third Quarter 2016 Financial Results and Company Update

BERKELEY, CA--(Marketwired - November 07, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2016.The...
October 27, 2016 07:00 ET | Source: Dynavax Technologies

Dynavax Secures Committed Financing From Deerfield for $100 Million of Senior Secured Notes

BERKELEY, CA--(Marketwired - October 27, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has entered into a note purchase agreement with one or more funds of Deerfield...
October 26, 2016 09:00 ET | Source: Dynavax Technologies

Dynavax Presents Data Showing That HEPLISAV-B Provides Significantly Higher Seroprotection Rates Against Hepatitis B Infection in Populations Known to Have a Reduced Immune Response to Currently Licensed Vaccines

BERKELEY, CA--(Marketwired - October 26, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational...
October 09, 2016 07:00 ET | Source: Dynavax Technologies

Dynavax Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, at ESMO Annual Congress

BERKELEY, CA--(Marketwired - October 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101,...
September 04, 2016 20:20 ET | Source: Dynavax Technologies

Dynavax Provides Regulatory Update on HEPLISAV-B

BERKELEY, CA--(Marketwired - September 04, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation...
August 05, 2016 17:51 ET | Source: Dynavax Technologies

Dynavax Reports Second Quarter 2016 Financial Results

BERKELEY, CA--(Marketwired - August 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016.The Company...
August 05, 2016 17:31 ET | Source: Dynavax Technologies

Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B

BERKELEY, CA--(Marketwired - August 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the Vaccines and Related Biological Products Advisory Committee (VBRPAC) will...
June 11, 2016 11:00 ET | Source: Dynavax Technologies

Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions

BERKELEY, CA--(Marketwired - June 11, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis...